Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IOLs in the ambulatory surgical center setting

This article was originally published in The Gray Sheet

Executive Summary

Requests for CMS to review the "appropriateness" of the $50 new technology intraocular lens payment will be accepted until March 29. The agency is required by statute to review the amount every five years. Advanced Medical Optics contends that the ASC system should be reformed to evaluate new technology every year (1"The Gray Sheet" Dec. 8, 2003, p. 11)...

You may also be interested in...



Cataract Procedures Could See Higher ASC Reimbursement Under Rx Bill

GAO will conduct a study by Jan. 1, 2005 examining the feasibility of using hospital OPPS claims data as a basis to set payment rates for ambulatory surgical centers, under a provision in the Medicare bill

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.

How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies

UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel